Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490796 | 0.94 | BRD4 (0.44) | BRD4 | |
| SCHEMBL5340518 | 0.92 | BRD4 (0.36) | BRD4BCHEADORA3ADORA2AMEN1 | |
| SCHEMBL5027830 | 0.86 | BRD4 (0.31) | BRD4 | |
| SCHEMBL5031347 | 0.83 | BRD4 (0.40) | BRD4BCHEADORA3ADORA2AMALT1 | |
| SCHEMBL14208872 | 0.80 | BRD4 (0.33) | BRD4 | |
| SCHEMBL4793343 | 0.79 | MAPT (0.37) | MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL4243097 | 0.79 | ALDH1A1 (0.34) | MEN1GAAKMT2AHTTALDH1A1 | |
| SCHEMBL1490507 | 0.78 | BRD4 (0.43) | BRD4 | |
| SCHEMBL5616460 | 0.78 | MAPT (0.39) | MEN1GAAKMT2AHTTALDH1A1 | |
| SCHEMBL5034574 | 0.77 | GAA (0.36) | BRD4BCHEADORA3ADORA2AMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20050032829-A1 | Process for imidazo[4,5-c]pyridin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | PAICS, HTR4, PNPO | BRD4 142/4885BCHE 3210/4885ADORA3 331/4885 |
| US-20050032829-A1 | Process for imidazo[4,5-c]pyridin-4-amines | PAICS, HTR4, PNPO | BRD4 142/4885BCHE 3210/4885ADORA3 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.